ResearcherUniversity of ConnecticutNo recent work listed

Lindsay L. Hollander

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9065-5024; OpenAlex author ID A5022099532. Sources: OpenAlex.

Their work

Papers: 2 (first author 1, last author 0)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 5

Papers, trials and grants by year

2015: 1 paper · 2016: 1 paper

Papers 2

Inhibition of renalase expression and signaling has antitumor activity in pancreatic cancer. First author DOI 10.1038/srep22996 ↗
The novel tumor angiogenic factor, adrenomedullin-2, predicts survival in pancreatic adenocarcinoma. Co-author DOI 10.1016/j.jss.2014.11.002 ↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Xiaojia Guo · 2 shared papers, 2015–2016 · strength 0.13
- Paper The novel tumor angiogenic factor, adrenomedullin-2, predicts survival in pancreatic adenocarcinoma. DOI 10.1016/j.jss.2014.11.002 ↗
- Paper Inhibition of renalase expression and signaling has antitumor activity in pancreatic cancer. DOI 10.1038/srep22996 ↗
Charles H. Cha · 2 shared papers, 2015–2016 · strength 0.13
- Paper The novel tumor angiogenic factor, adrenomedullin-2, predicts survival in pancreatic adenocarcinoma. DOI 10.1016/j.jss.2014.11.002 ↗
- Paper Inhibition of renalase expression and signaling has antitumor activity in pancreatic cancer. DOI 10.1038/srep22996 ↗
Ronald R. Salem · 1 shared paper, 2015 · strength 0.07
- Paper The novel tumor angiogenic factor, adrenomedullin-2, predicts survival in pancreatic adenocarcinoma. DOI 10.1016/j.jss.2014.11.002 ↗
Fred S. Gorelick · 1 shared paper, 2016 · strength 0.06
- Paper Inhibition of renalase expression and signaling has antitumor activity in pancreatic cancer. DOI 10.1038/srep22996 ↗
Gary V. Désir · 1 shared paper, 2016 · strength 0.06
- Paper Inhibition of renalase expression and signaling has antitumor activity in pancreatic cancer. DOI 10.1038/srep22996 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.